[go: up one dir, main page]

AR077476A2 - Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos - Google Patents

Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos

Info

Publication number
AR077476A2
AR077476A2 ARP100102568A ARP100102568A AR077476A2 AR 077476 A2 AR077476 A2 AR 077476A2 AR P100102568 A ARP100102568 A AR P100102568A AR P100102568 A ARP100102568 A AR P100102568A AR 077476 A2 AR077476 A2 AR 077476A2
Authority
AR
Argentina
Prior art keywords
vitronectine
receiver
compounds
pharmaceutical compositions
preparation procedure
Prior art date
Application number
ARP100102568A
Other languages
English (en)
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Publication of AR077476A2 publication Critical patent/AR077476A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) en todas las formas isomeras, solas o en mezcla, así como sus sales de adicion fisiologicamente aceptables, en donde G representa 1,2,3,4-tetrahidro-1,8-naftiridin-7-ilo; R1 representa metilo; R2 representa metilo; R3 representa benciloxicarbonilo; y R4 representa OH o t-butoxi.
ARP100102568A 2002-11-19 2010-07-15 Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos AR077476A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant

Publications (1)

Publication Number Publication Date
AR077476A2 true AR077476A2 (es) 2011-08-31

Family

ID=32187700

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030104254A AR042068A1 (es) 2002-11-19 2003-11-18 Derivados de antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, sus aplicaciones como medicamentos y los compuestos farmaceuticos que contienen
ARP100102568A AR077476A2 (es) 2002-11-19 2010-07-15 Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030104254A AR042068A1 (es) 2002-11-19 2003-11-18 Derivados de antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, sus aplicaciones como medicamentos y los compuestos farmaceuticos que contienen

Country Status (27)

Country Link
US (2) US7582640B2 (es)
EP (2) EP2070914B1 (es)
JP (1) JP4567459B2 (es)
KR (1) KR101140752B1 (es)
CN (2) CN1738817B (es)
AR (2) AR042068A1 (es)
AT (2) ATE431825T1 (es)
AU (2) AU2003299330B2 (es)
BR (1) BR0316307A (es)
CA (1) CA2506310C (es)
CO (1) CO5700761A2 (es)
CY (1) CY1112218T1 (es)
DE (1) DE60327712D1 (es)
DK (2) DK1565467T3 (es)
ES (2) ES2325616T3 (es)
FR (1) FR2847254B1 (es)
IL (2) IL168136A (es)
MA (1) MA27492A1 (es)
MX (1) MXPA05005340A (es)
NO (1) NO20052491L (es)
PL (1) PL376866A1 (es)
PT (2) PT2070914E (es)
RU (1) RU2412185C2 (es)
SI (2) SI2070914T1 (es)
TW (1) TW200412969A (es)
WO (1) WO2004048375A1 (es)
ZA (1) ZA200502850B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
JP7083073B2 (ja) 2018-08-17 2022-06-09 オクスリオン ナムローゼ フエンノートシャップ インテグリンアンタゴニスト
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A4 (en) 2020-06-29 2024-07-24 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
WO1994008577A1 (en) 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU702661B2 (en) 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
PL330915A1 (en) 1996-06-28 1999-06-07 Merck Patent Gmbh Phenylaniline derivatives as inhibitors of integrin
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
AU752882B2 (en) 1998-01-23 2002-10-03 Aventis Pharma Deutschland Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
AU5336299A (en) * 1998-08-07 2000-02-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
ATE248646T1 (de) * 1999-10-05 2003-09-15 Element Six Pty Ltd Wachstum von diamantclustern
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
AU2009212779B2 (en) 2011-09-01
EP2070914B1 (fr) 2011-08-03
EP2070914A1 (fr) 2009-06-17
TW200412969A (en) 2004-08-01
US7582640B2 (en) 2009-09-01
EP1565467A1 (fr) 2005-08-24
FR2847254A1 (fr) 2004-05-21
AU2009212779A1 (en) 2009-09-17
BR0316307A (pt) 2005-09-27
DK2070914T3 (da) 2011-11-21
ES2325616T3 (es) 2009-09-10
CN101928287A (zh) 2010-12-29
RU2005119163A (ru) 2006-02-27
NO20052491D0 (no) 2005-05-23
US20060052398A1 (en) 2006-03-09
ATE518842T1 (de) 2011-08-15
US20090149476A1 (en) 2009-06-11
CY1112218T1 (el) 2015-12-09
ES2369561T3 (es) 2011-12-01
EP1565467B1 (fr) 2009-05-20
PL376866A1 (pl) 2006-01-09
NO20052491L (no) 2005-05-23
CA2506310A1 (fr) 2004-06-10
AR042068A1 (es) 2005-06-08
RU2412185C2 (ru) 2011-02-20
KR101140752B1 (ko) 2012-05-03
AU2003299330B2 (en) 2009-09-17
WO2004048375A1 (fr) 2004-06-10
ZA200502850B (en) 2005-10-25
SI1565467T1 (sl) 2009-10-31
IL205693A (en) 2011-06-30
IL168136A (en) 2012-06-28
PT1565467E (pt) 2009-07-15
CA2506310C (fr) 2014-04-08
DK1565467T3 (da) 2009-09-14
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
KR20050083926A (ko) 2005-08-26
MXPA05005340A (es) 2005-11-17
HK1129372A1 (en) 2009-11-27
JP2006508999A (ja) 2006-03-16
HK1076277A1 (en) 2006-01-13
JP4567459B2 (ja) 2010-10-20
SI2070914T1 (sl) 2012-02-29
CN1738817A (zh) 2006-02-22
FR2847254B1 (fr) 2005-01-28
ATE431825T1 (de) 2009-06-15
PT2070914E (pt) 2011-10-12
DE60327712D1 (de) 2009-07-02
CO5700761A2 (es) 2006-11-30
AU2003299330A1 (en) 2004-06-18
CN1738817B (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
AR077476A2 (es) Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos
UY27516A1 (es) Bencimidazoles
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
ECSP077185A (es) Derivados de piridina
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
UY28510A1 (es) Compuestos quimicos
UY28623A1 (es) Derivados de pirazol y usos de los mismos
UY27350A1 (es) Azaindoles
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
SE0202463D0 (sv) Novel compounds
UY27740A1 (es) Nuevos compuestos
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
UY29606A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
UY28763A1 (es) Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
SV2005001979A (es) "pirido[2,3-d]pirimidina-2,4-diaminas como inhibidores de pde 2 " ref. pc25123a
SG171471A1 (en) New benzimidazole derivatives
UY29893A1 (es) Derivados de pirazina
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR044453A1 (es) Derivados de metoxi-pirazin-tienil sulfonamida
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee